#United States #New York #PROCEPT BioRobotics #PRCT #SueWallSt

Upcoming Class Action Against PROCEPT BioRobotics Corporation

On February 25, 2026, investors were jolted when PROCEPT BioRobotics Corporation disclosed troubling data concerning their handpiece sales and corresponding procedure demands. The revelation highlighted a staggering decline in their stock price, plunging by more than 75% from its high, leading to serious concerns about the company's transparency and reliability in reporting its operational performance.

The latest developments indicate that a securities class action has been initiated on behalf of shareholders who acquired shares during the Class Period from February 28, 2024, to February 25, 2026. As part of this lawsuit, affected investors are encouraged to determine their eligibility to recover losses resulting from the apparent discrepancies in reported handpiece sales versus actual procedure demand.

Truist Securities analysts were particularly concerned after it became evident that PROCEPT had significantly overstated handpiece sales figures. The previously disclosed financial metrics hinted at a troubling gap between handpiece sales and actual procedures conducted — a discrepancy of 8% to 16% per quarter since the first quarter of 2023. This led investors to question whether the company had been supplying discounted handpieces rather than meeting actual market demands.

Furthermore, the stock which once stood at approximately $100.00 per share now finds itself valued below $25.00. This extreme shift has raised alarms as the firm reported that its unit sales experienced a dramatic contraction, exemplified by a drop from roughly 13,200 in Q3 2025 to around 9,400 in Q4 2025.

Why This Matters to Investors

The root cause for investors' distress lies in the misunderstanding of key operational metrics. Analysts had relied heavily on reported handpiece sales as an indicator of the company's health and ongoing revenue from AquaBeam procedures. However, as the actual data came to light, it became evident that the company's reassurances regarding consistent handpiece sales were misleading. As attorney Joseph E. Levi noted, when investor expectations are based on incomplete or misleading information, it can lead to substantial financial harm once the truth is unveiled.

Wall Street's scrutiny of PROCEPT's disclosures has amplified, as analysts confronted the firm regarding previous explanations for revenue issues that attributed fluctuations to external factors. Investors now face the challenging task of navigating the aftermath of flawed disclosures, which can severely impact their financial standing and market confidence.

Frequently Asked Questions About the Lawsuit

1. What is the PRCT class action lawsuit about?
The lawsuit alleges that PROCEPT BioRobotics Corporation made materially false and misleading statements that led to a significant decline in share value, affecting investors who purchased during the Class Period.

2. What court is handling this class action?
This case has been filed in the United States District Court for the Northern District of California, under the Private Securities Litigation Reform Act of 1995.

3. Can I still recover losses if I sold my PRCT shares?
Yes, eligibility for compensation is based on purchase timing and losses incurred, regardless of current ownership status.

4. Do I need to appear in court?
Most class members do not need to testify or appear in court. Claims are usually settled without individual appearances.

Given the significant implications for investors, those who acquired shares during the Class Period should closely monitor developments in this case. Legal representation and advice can help investors navigate the complexities of the ongoing litigation and understand their rights in the process. Interested parties can reach out to SueWallSt for further guidance and potential recovery options.

For more information about participating in this class action lawsuit or to understand your rights as an investor, please contact Levi Korsinsky LLP.